Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23225591 | 1.00 | TOP2A (0.35) | TOP2AMAPTHPGD | |
| SCHEMBL12243150 | 0.75 | — | — | |
| SCHEMBL19987344 | 0.74 | TOP2A (0.39) | TOP2AMAPTHPGD | |
| SCHEMBL20380385 | 0.73 | PYGB (0.31) | — | |
| SCHEMBL12243149 | 0.73 | PYGB (0.31) | — | |
| SCHEMBL17010850 | 0.73 | PYGB (0.31) | — | |
| SCHEMBL17010849 | 0.72 | — | — | |
| SCHEMBL23992637 | 0.71 | TOP2A (0.38) | TOP2AMAPTHPGD | |
| SCHEMBL19974561 | 0.70 | TOP2A (0.37) | TOP2AMAPTHPGD | |
| SCHEMBL20380386 | 0.70 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403497-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2021-12-30 | — | — | US | disclosed |
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | GILEAD SCIENCES, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403497-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1`-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, TYMS | TOP2A 106/4885MAPT 4073/4885HPGD 1732/4885 |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | TOP2A 1645/4885MAPT 3605/4885HPGD 488/4885 |
| US-10023600-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | TOP2A 105/4885MAPT 4100/4885HPGD 1749/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | TOP2A 1498/4885MAPT 3367/4885HPGD 1530/4885 |
| US-10988498-B2 | Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs | PNP, TYMP, CDA | TOP2A 105/4885MAPT 4100/4885HPGD 1749/4885 |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, NUDT1 | TOP2A 1498/4885MAPT 3367/4885HPGD 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.